Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respiratory, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. It exports its p
| Current Price | ₹1,789.90 |
|---|---|
| Market Cap | ₹4,29,457 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 37.4 |
| Return on Equity | 14.72% |
| 52-Week Range | ₹1,548.00 – ₹1,916.60 |
| Beta (1Y) | -0.1 |
| Dividend Yield | 0.56% |
1. Pharmaceuticals-100%
Sun Pharmaceutical Industries Limited is trading at ₹1,789.90, with a market capitalisation of ₹4,29,457 Cr.
Sun Pharmaceutical Industries Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Medicinal Chemicals and Botanical Products).
Sun Pharmaceutical Industries Limited has a P/E of 37.4 and a return on equity of 14.72%.